News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

WuXi PharmaTech Co., Ltd. Passes European Medicines Evaluation Agency Inspection of Its GMP Manufacturing and Analytical Testing Facilities in Shanghai


2/24/2010 8:41:10 AM

SHANGHAI, China, Feb. 23 /PRNewswire-Asia/ -- WuXi PharmaTech , a leading pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China and the United States, announced today that it received the formal certificate of GMP compliance from the Medical Products Agency (MPA) of Sweden, acting on behalf of the European Medicines Agency (EMEA), for its c-GMP drug product manufacturing and analytical testing facilities located in Shanghai.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO )

WuXi produces solid oral dosage forms-tablets and capsules-for use in clinical trials in its Shanghai c-GMP manufacturing facility. In its analytical testing facility, WuXi develops and validates methods of analyzing APIs and formulated drug products for properties such as potency, purity and solubility. The company also offers compound stability tests and tests necessary for the release of APIs and drug products for clinical trial use. WuXi also delivers services related to regulatory compliance with chemistry, manufacturing and controls, or CMC, requirements, including creation of a readiness testing package for an Investigational New Drug filing and development of a full CMC package.

"We are very pleased to have passed this EMEA audit," commented Dr. Ge Li, Chairman and Chief Executive Officer of WuXi PharmaTech. "The agency's inspection outcome confirms that these two facilities meet international GMP standards.

"We pride ourselves on the quality of our facilities, processes, and people," Dr. Li continued. "Research manufacturing and analytical testing are important functions in a continuum of integrated drug discovery and development services that WuXi provides to our global customers. Our mission is to help our global customers to improve the success of discovery and shorten the time of development of new medical products."

CONTACT: Ronald Aldridge, Director of Investor Relations, WuXi PharmaTech
(Cayman) Inc., +1-201-585-2048, or Ron_Aldridge@wuxiapptec.com; or
Stephanie Liu, Associate Director of Corporate Communications Department,
+86-21-5046-4362, or pr@wuxiapptec.com

Web site: http://www.wuxiapptec.com/


Read at BioSpace.com
Read at ChinaBio Today


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES